medigraphic.com
Colegio de Medicina Interna de México.

2009, Number 4

<< Back Next >>

Med Int Mex 2009; 25 (4)

Metabolic syndrome prevalence related to uric acid levels

Reyes JAE, Navarro J, Cruz IM, Castro DLJ, Landgrave GJ, Narváez PC, Landgrave GI, Oregón LA, Espinosa LFR

Language: Spanish
References: 24
Page: 278-284
PDF size: 107.92 Kb.


ABSTRACT

Background: Metabolic syndrome prevalence related to uric acid levels is unknown. In patients with metabolic syndrome decreased renal excretion of urates may explain the increased frequency of hyperuricemia.
Objective: To determine the prevalence of metabolic syndrome related to different levels of uric acid.
Patients and methods: A prevalence study done in users of Hospital Central Norte, Petroleos Mexicanos, Mexico City, 18-65 years old. Patients with known metabolic syndrome, chronic renal diseases, septicemia, multiple organ dysfunction syndrome, pregnancy or current treatment of hyperuricemia were excluded. Levels of uric acid, triglycerides, HDL, glucose, blood pressure and waist circumference were determined. Patients were divided into four groups according to their levels of uric acid. Group 1: ‹ 6 mg/dL; group 2: 6-7.9 mg/dL, group 3: 8-9.9 mg/dL and group 4: › 10 mg/dL.
Results: 770 patients were studied: 460 women. Sixty-one percent of men and fourty-seven percent of women had metabolic syndrome. Lower levels (6 mg/dL) of uric acid were found in 28% and 7% of men and women, respectively. Seventy-fi ve percent of men had levels of uric acid between 6 and 7.9 mg/dL and 20% of women. Levels of uric acid of 8-9.9 mm/dL were found in 100% and 20% of men and women. Levels higher than 10 mg/dL had a prevalence of 100% in both sexes.
Conclusions: Prevalence of metabolic syndrome is substancially increasing with elevated acid uric levels.


REFERENCES

  1. Laclaustra GM, Bergua MC, Pascual CI. Síndrome metabólico. Concepto y fi siopatología. Rev Esp Cardiol 2005;5:S3DS10D.

  2. Moller DE, Flier JS. Insulin resistance: Mechanisms, syndromes and implications. N Engl J Med 1991;325:938-45.

  3. Grupo de Trabajo de Resistencia a la Insulina de la Sociedad Española de Diabetes. Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a la diabetes tipo 2. Med Clin (Barc) 2002;119:458-63.

  4. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995;13:1457-62.

  5. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998;8:250-61.

  6. Johnson RJ, Kivlighn SD, Kim SG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999;33:225-34.

  7. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-97.

  8. Hyon KCh, Earls Ford. Prevalence of the Metabolic Syndrome in Individuals with Hyperuricemia.The American Journal of Medicine 2007;120:442-47.

  9. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.

  10. Alberti KG, Zimmet PZ, for the WHO Consultation. Defi nition, diagnosis and classifi cation of diabetes mellitus, personal report of a WHO consultation. Diabetes Med 1998;15:539-53.

  11. Grundy SM, Cleeman JI, Merz CN, Brewer HB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.

  12. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed defi nitions. Diabetes Care 2003;26(3):575-81.

  13. Martínez de Morentin BE, Rodríguez MC, Martínez JA. Síndrome metabólico, resistencia a la insulina y metabolismo tisular. Endocrinol Nutr 2003;50:324-33.

  14. Michael A, Becker, MA, Meenakshi J. Hyperuricemia and Associated Diseases. Rheum Dis Clin N Am 2006;32:275-93.

  15. Bastarrachea RA, Shelley A, Cole A, Comuzzie G. Genómica de la regulación del peso corporal: mecanismos moleculares que predisponen a la obesidad. Med Clin (Barc) 2004;123:104-17.

  16. Cheng LS, Davis RC, Raffel LJ, Xiang AH, Wang N, Quinones M, et al. Coincident linkage of fasting plasma insulin and blood pressure to cromosoma 7q in hypertensive hispanic families. Circulation 2001;104:1255-60.

  17. Bruce F, Culleton MD, Martin G, Larson SD. Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study. Ann Intern Med 1999;131:7-13.

  18. Chonchol M, Shlipak MG, Katz R. Relationship of Uric Acid With Progression of Kidney Disease. American Journal of Kidney Diseases 2007;50(2):239-47.

  19. Wyngaarden JB, Kelley WN. Gout and hyperuricemia. New York: Grune and Stratton, 1976.

  20. Gibson T, Waterworth R, Hatfi eld P, et al. Hyperuricemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol 1984;23:276-82.

  21. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994;8:677-81.

  22. Rapado A. Relationship between gout and arterial hypertension. Adv Exp Med Biol 1974;41B: 451-9.

  23. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005;25:43 -9.

  24. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure independent mechanism. Am J Physiol Renal Physiol 2002;282:991-7.




2020     |     www.medigraphic.com